@article{86b643ae6ca04a899c48e69c56697b19,
title = "Practical guidance for planning resources required to support publicly-funded adaptive clinical trials",
abstract = "Adaptive designs are a class of methods for improving efficiency and patient benefit of clinical trials. Although their use has increased in recent years, research suggests they are not used in many situations where they have potential to bring benefit. One barrier to their more widespread use is a lack of understanding about how the choice to use an adaptive design, rather than a traditional design, affects resources (staff and non-staff) required to set-up, conduct and report a trial. The Costing Adaptive Trials project investigated this issue using quantitative and qualitative research amongst UK Clinical Trials Units. Here, we present guidance that is informed by our research, on considering the appropriate resourcing of adaptive trials. We outline a five-step process to estimate the resources required and provide an accompanying costing tool. The process involves understanding the tasks required to undertake a trial, and how the adaptive design affects them. We identify barriers in the publicly funded landscape and provide recommendations to trial funders that would address them. Although our guidance and recommendations are most relevant to UK non-commercial trials, many aspects are relevant more widely.",
keywords = "Adaptive designs, Adaptive clinical trials, Clinical trials, Efficiency, Resource requirements, Trial coordination",
author = "Wason, {James M S} and Munyaradzi Dimairo and Katie Biggs and Sarah Bowden and Julia Brown and Laura Flight and Jamie Hall and Thomas Jaki and Rachel Lowe and Philip Pallmann and Pilling, {Mark A} and Claire Snowdon and Sydes, {Matthew R} and Villar, {Sofia S} and Weir, {Christopher J} and Nina Wilson and Christina Yap and Helen Hancock and Rebecca Maier",
note = "Funding Information: The Cancer Research UK Clinical Trials Unit (CRCTU) receive infrastructure funding from Cancer Research UK. Funding Information: The Centre for Trials Research, Cardiff University receives infrastructure funding from Health and Care Research Wales and Cancer Research UK. CJW was supported in this work by NHS Lothian via Edinburgh Clinical Trials Unit. TJ received funding from UK Medical Research Council (MC_UU_00002/14). SSV received funding from UK Medical Research Council (MC_UU_00002/15). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20,014). The Leeds Institute of Clinical Trials Research receives infrastructure funding from the NIHR and CRUK. Funding Information: MRS is supported for this work through the Medical Research Council (MC_UU_00004/08). Funding Information: This report is independent research supported by the National Institute for Health Research (NIHR130351). JMSW is funded by a NIHR Research Professorship (NIHR301614). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care (DHSC). Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = aug,
day = "10",
doi = "10.1186/s12916-022-02445-7",
language = "English",
volume = "20",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",
}